RAC Regulatory Agency Interactions Questions and Answers 1 — Questions and Answers
Question 1: A sponsor's novel drug development program is on clinical hold due to safety concerns. The sponsor has submitted a complete response to the hold issues, but the agency and sponsor agree that the path forward is unclear. Which type of formal meeting with the FDA is most appropriate to request to resolve the impasse?
- Type B Meeting
- Type C Meeting
- Type A Meeting (Correct answer)
- Pre-IND Meeting
Correct answer: Type A Meeting
A Type A meeting is specifically designed for situations that are delaying the overall product development, such as resolving a clinical hold or addressing a dispute where the development program is stalled. Type B meetings are for pre-defined milestones (e.g., pre-NDA), and Type C meetings are for any other topic not covered by Type A or B. A Pre-IND meeting would have occurred before the IND was filed and the clinical hold was placed.
Question 2: When preparing a briefing package for a Pre-Submission (Q-Sub) meeting with the FDA for a new medical device, which of the following is the MOST critical component to include?
- A complete list of all anticipated marketing claims.
- Detailed financial projections for the first five years.
- Specific, forward-looking questions for the agency on which feedback is sought. (Correct answer)
- The final, locked-down version of the device's Instructions for Use (IFU).
Correct answer: Specific, forward-looking questions for the agency on which feedback is sought.
The primary purpose of a Q-Submission is to obtain feedback from the agency to guide product development and submission preparation. Therefore, including clear, specific, and well-reasoned questions is the most critical component, as these questions will frame the entire discussion and the feedback provided by the FDA. The other elements, while potentially part of the overall package, are secondary to the core goal of getting answers to specific regulatory, technical, or clinical questions.
Question 3: A pharmaceutical manufacturer receives an FDA Form 483 with three inspectional observations at the close-out of a GMP inspection. What is the most critical immediate action for the company?
- Wait for the official Establishment Inspection Report (EIR) before taking any action.
- Immediately file a formal dispute with the agency's legal counsel.
- Begin remediation but refrain from communicating with the FDA until all actions are complete.
- Submit a comprehensive written response within 15 business days outlining corrective and preventive actions (CAPAs). (Correct answer)
Correct answer: Submit a comprehensive written response within 15 business days outlining corrective and preventive actions (CAPAs).
The FDA expects a formal written response to a Form 483 within 15 business days. A timely and thorough response that acknowledges the observations and details the company's CAPA plan is crucial. This demonstrates a commitment to compliance and can help prevent the escalation of regulatory action, such as the issuance of a Warning Letter.
Question 4: A company is developing a novel medicinal product in Europe and seeks guidance from the European Medicines Agency (EMA) on its proposed clinical development strategy. Which formal procedure should the company utilize for this purpose?
- Centralised Procedure Application
- Scientific Advice (Correct answer)
- Marketing Authorisation Application
- Mutual Recognition Procedure
Correct answer: Scientific Advice
Scientific Advice is the specific procedure offered by the EMA for developers to get non-binding guidance on the appropriate tests and studies required for the development of a medicine. This process helps ensure that the development plan aligns with regulatory expectations before major resources are committed. The other options are procedures for obtaining marketing authorization, not for seeking developmental guidance.
Question 5: Following a formal meeting with the FDA, the sponsor receives the agency's official meeting minutes and identifies a significant discrepancy regarding a key agreement on the statistical analysis plan. What is the most appropriate action for the sponsor?
- Formally contact the FDA within the specified timeframe to request a clarification or correction to the minutes. (Correct answer)
- Accept the FDA's minutes as legally binding and immediately alter the clinical trial design.
- Proceed with the trial based on their own understanding and address the discrepancy in the final NDA submission.
- Send a letter of complaint directly to the FDA Ombudsman.
Correct answer: Formally contact the FDA within the specified timeframe to request a clarification or correction to the minutes.
Regulatory agencies have established processes that allow sponsors to review and provide comments or request clarifications on official meeting minutes, typically within a specific timeframe. This is the correct and necessary step to ensure the official record is accurate and reflects a mutual understanding. Ignoring the discrepancy or accepting an incorrect record can lead to significant regulatory risk later in development.
Question 6: Which of the following best describes the role of an FDA Advisory Committee in the product approval process?
- To negotiate labeling and post-marketing commitments directly with the sponsor.
- To provide a final, legally binding decision on the approvability of a product.
- To conduct its own independent audits of the sponsor's clinical trial data.
- To provide independent, expert advice and recommendations to the FDA, which the agency considers in its final decision. (Correct answer)
Correct answer: To provide independent, expert advice and recommendations to the FDA, which the agency considers in its final decision.
FDA Advisory Committees are panels of external experts who provide non-binding scientific and medical advice to the agency. The FDA makes the final decision on product approval but gives significant weight to the committee's recommendations. The committee's role is purely advisory; it does not make binding decisions or negotiate directly with sponsors.
RAC Regulatory Agency Interactions Questions and Answers 1
A sponsor's novel drug development program is on clinical hold due to safety concerns.
The sponsor has submitted a complete response to the hold issues, but the agency and sponsor agree that the path forward is unclear.
Which type of formal meeting with the FDA is most appropriate to request to resolve the impasse?